LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Detecting genetic and environmental modifiers of penetrance and disease expression
Objective: The international multicenter LIPAD study is a deep-phenotyping, follow-up study to ROPAD (Rostock Parkinson’s Disease Study) with the aim to systematically characterize Parkinson's disease…Characterizing Global Cohorts with Monogenic Parkinson’s Disease
Objective: To clinically and genetically characterize a global sample of subjects with monogenic Parkinson’s disease (mPD) and unaffected mutation carriers. Background: Publications on patients with…The role of peripheral T- and B-lymphocytes in LRRK2-mediated Parkinson’s disease
Objective: To test the hypothesis the neurodegenerative cascade in the CNS that leads to Parkinson’s disease (PD) is initiated by signals emanating from the peripheral…Distinct compensatory and maladaptive wiring patterns in genotypic Parkinson’s disease
Objective: Although disease networks have been identified in Parkinson’s disease (PD) using functional imaging, it is unclear whether these represent maladaptive or compensatory responses to…Premotor compensatory mechanisms in Parkinson’s disease with LRRK2-R1441H mutation
Objective: To investigate the time course of modifications in dopaminergic terminals during the premotor phase in LRRK2 genetically determined Parkinson’s disease (PD). Background: Increased dopamine…Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations
Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease
Objective: Do clinical cognitive profiles and CSF characterisitcs of Abeta1_42, total-tau, phospho-tau and alpha-synuclein during lifetime correspond to histopathological findings post-mortem in LRKK2-associated Parkinson’s disease…Increased level of a lysosomal phospholipid, BMP, in urine of LRRK2 G2019S mutation carriers with or without Parkinson’s disease: implications for therapeutic development
Objective: To study alterations in urinary phospholipids as biomarkers of LRRK2 mutations and Parkinson’s disease (PD) status. Background: LRRK2 mutations are a common cause of…Investigating the cellular role of LRRK2 in the immune system
Objective: The objective of this project is to investigate the effect of Leucine Rich-Repeat Kinase 2 (LRRK2) dysfunction in the signalling mechanisms in macrophages and…Structural connectivity changes in G2019S-LRRK2 gene mutation carriers without manifest Parkinson’s disease
Objective: We hypothesised that abnormal sprouting of serotonergic terminals in the hypothalamus may lead to abnormal structural connectivity, which can be measured with diffusion tensor…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 19
- Next Page »